Hepatitis C virus infection and the temporal trends in the risk of liver cancer: a national register-based cohort study in SwedenShow others and affiliations
2020 (English)In: Cancer Epidemiology, Biomarkers and Prevention, ISSN 1055-9965, E-ISSN 1538-7755, Vol. 29, no 1, p. 63-70Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: In many countries, including Sweden, the birth cohorts with the highest prevalence of hepatitis C virus (HCV) infection have now reached the ages with high risk of primary liver cancer (PLC). The aims were to investigate the temporal trends in PLC incidence and the relative risks of PLC among people diagnosed with HCV-infection between 1990 and 2015.
METHODS: The HCV-cohort (n: 52,853) was compared with a matched non-HCV comparison-cohort (n: 523,649). Both the Cancer (CR) and Death registers (DR) were used for follow-up. The crude and age-standardised PLC incidence rates were calculated. The relative risk was estimated as standardized incidence ratios (SIR) and as hazard ratios (HR) using stratified Cox hazards regression.
RESULTS: There were 1,609 with PLC-diagnosis in the HCV-cohort, the annual number increased continuously with the crude incidence rate reaching 4.56 per 1,000 person-years in 2013, while remaining low and stable in the comparison-cohort. In the HCV-cohort, the age-standardised PLC incidence rates per 1,000 person-years remained relatively constant at 2.64 (95% CI: 1.54, 3.75) in 2000 and 3.31 (2.51, 4.12) in 2014. The highest SIR was 73 (65.9, 79.5) among those infected for 35-40 years; and the highest HR was 65.9 (55.9, 77.6) for men and 62.2 (31.9, 121.1) for women.
CONCLUSIONS: There was a considerable increase in PLC-incidence over time and an extremely high relative risk in the population with HCV-infection for more than 35 years.
IMPACT: The national HCV-associated PLC-incidence should be monitored in future studies to evaluate the effect of DAA-treatment.
Place, publisher, year, edition, pages
American Association for Cancer Research , 2020. Vol. 29, no 1, p. 63-70
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-77946DOI: 10.1158/1055-9965.EPI-19-0769ISI: 000521285100008PubMedID: 31719064Scopus ID: 2-s2.0-85077926564OAI: oai:DiVA.org:oru-77946DiVA, id: diva2:1371752
Note
Funding Agencies:
Research ALF grants from Region Örebro County OLL-683801
Nyckelfonden, Örebro, Sweden OLL-691511
2019-11-202019-11-202024-03-05Bibliographically approved